Dimensional Fund Advisors LP Boosts Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Dimensional Fund Advisors LP boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 594.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 331,300 shares of the company's stock after purchasing an additional 283,577 shares during the period. Dimensional Fund Advisors LP owned about 0.39% of Syndax Pharmaceuticals worth $4,378,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its position in shares of Syndax Pharmaceuticals by 343.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock valued at $27,292,000 after acquiring an additional 1,598,428 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,823 shares of the company's stock valued at $9,318,000 after purchasing an additional 8,876 shares during the period. Renaissance Technologies LLC bought a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $9,002,000. Trexquant Investment LP boosted its position in shares of Syndax Pharmaceuticals by 1,309.7% in the 4th quarter. Trexquant Investment LP now owns 471,292 shares of the company's stock worth $6,230,000 after purchasing an additional 437,859 shares in the last quarter. Finally, Altium Capital Management LLC acquired a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth $4,891,000.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. HC Wainwright restated a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Citigroup dropped their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Scotiabank lifted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a report on Tuesday, May 6th. Finally, StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Price Performance

SNDX traded up $0.10 during trading hours on Friday, reaching $9.05. The company's stock had a trading volume of 2,954,265 shares, compared to its average volume of 1,725,031. The stock has a market cap of $778.73 million, a PE ratio of -2.49 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07. The business's 50-day moving average is $12.10 and its 200-day moving average is $14.03.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.06. The firm had revenue of $20.04 million during the quarter, compared to analysts' expectations of $15.88 million. During the same period in the previous year, the firm earned ($0.85) EPS. The firm's revenue for the quarter was up 1900.0% compared to the same quarter last year. Analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).